Data / Research funding / Massachusetts / Radiation Monitoring Devices, Inc.
Radiation Monitoring Devices, Inc.: 5 NIH awards ($6.2M), fiscal years 2021 to 2026
Radiation Monitoring Devices, Inc. in Watertown, MA is funded under 5 NIH awards ($6.2M) in the NIH and NSF award files, read 2026-11-04. NIH fiscal years 2021 to 2025; NSF fiscal years 2022 to 2026.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- UEI
- SCKQA85YU4U4
- State
- Massachusetts
Awards
5 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|
| Semiconductor detector for low-dose, high-resolution dental DR imaging | NIH | National Institute of Dental & Craniofacial Research | 2022 to 2024 | $1,981,567 | September 16, 2022 | August 31, 2025 | CHRISTIAN, JAMES F | reporter.nih.gov |
| Tl-Halide Scintillators for TOF-PET | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2023 | $1,461,976 | August 1, 2022 | May 31, 2025 | GLODO, JAROSLAW | reporter.nih.gov |
| Ultra-dense and Fast Ceramic Scintillator for PET | NIH | National Cancer Institute | 2021 to 2022 | $1,302,118 | August 1, 2021 | April 30, 2024 | GLODO, JAROSLAW | reporter.nih.gov |
| Ultra-dense ceramic scintillator for BrainPET scanner | NIH | National Institute of Mental Health | 2023 to 2025 | $1,180,939 | August 4, 2023 | September 19, 2027 | GLODO, JAROSLAW | reporter.nih.gov |
| Directional sensor for radioluminescence microscopy of next-generation tumor models | NIH | National Cancer Institute | 2021 | $258,898 | August 10, 2021 | July 31, 2022 | MILLER, STUART R | reporter.nih.gov |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|
| 2025 | 1 | $905,751 | 0 | $0 |
| 2024 | 1 | $854,588 | 0 | $0 |
| 2023 | 3 | $1,772,087 | 0 | $0 |
| 2022 | 3 | $1,557,200 | 0 | $0 |
| 2021 | 3 | $1,095,872 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|
| Developing novel theory and methods for understanding the genetic architecture of complex human traits (R01 Clinical Trial Not Allowed) | PAR-25-255 | NIH | 93.242 | November 5, 2026 | Not listed | Same assistance listing 93.242 as 1 award here |
| Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed) | PAR-25-095 | NIH | 93.121 | November 6, 2026 | $350,000 | Same assistance listing 93.121 as 1 award here |
| Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) | RFA-CA-27-001 | NIH | 93.394 | November 10, 2026 | $150,000 | Same assistance listing 93.394 as 1 award here |
| Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) | RFA-CA-27-002 | NIH | 93.394 | November 10, 2026 | $300,000 | Same assistance listing 93.394 as 1 award here |
| Advancing Real-World Effectiveness Evidence for Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) | RFA-MH-27-150 | NIH | 93.242 | November 13, 2026 | Not listed | Same assistance listing 93.242 as 1 award here |
| Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional) | PAR-25-370 | NIH | 93.121 | November 16, 2026 | $50,000 | Same assistance listing 93.121 as 1 award here |
| Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed) | PAR-25-096 | NIH | 93.121 | November 17, 2026 | $200,000 | Same assistance listing 93.121 as 1 award here |
| Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) | PAR-25-369 | NIH | 93.121 | November 18, 2026 | Not listed | Same assistance listing 93.121 as 1 award here |
| Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional) | PAR-25-371 | NIH | 93.242 | November 18, 2026 | Not listed | Same assistance listing 93.242 as 1 award here |
| Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required) | PAR-25-226 | NIH | 93.242 | November 19, 2026 | Not listed | Same assistance listing 93.242 as 1 award here |
| NCI Research Specialist Award for Core and Laboratory-based Scientists (R50 Clinical Trial Not Allowed) | PAR-27-088 | NIH | 93.394 | November 20, 2026 | Not listed | Same assistance listing 93.394 as 1 award here |
| HEAL Initiative: Pain Research Enhancement Program (PREP) (R15 Clinical Trial Optional) | RFA-AT-25-003 | NIH | 93.121 | November 23, 2026 | $375,000 | Same assistance listing 93.121 as 1 award here |
| Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional) | PA-23-317 | NIH | 93.394 | November 24, 2026 | Not listed | Same assistance listing 93.394 as 1 award here |
| Maximizing the Scientific Value of Data Generated by the Environmental Influences on Child Health Outcomes (ECHO) Program: Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (F32) | RFA-OD-27-008 | NIH | 93.121 | December 2, 2026 | Not listed | Same assistance listing 93.121 as 1 award here |
| Emerging Global Leader Award (K43 Independent Clinical Trial Required) | PAR-24-295 | NIH | 93.242 | December 3, 2026 | Not listed | Same assistance listing 93.242 as 1 award here |
| Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed) | PAR-24-296 | NIH | 93.121 | December 3, 2026 | Not listed | Same assistance listing 93.121 as 1 award here |
| NIH Research Software Engineer (RSE) Award (R50 Clinical Trials Not Allowed) | RFA-OD-24-011 | NIH | 93.286 | December 4, 2026 | Not listed | Same assistance listing 93.286 as 1 award here |
| Small Business Transition Grant for New Entrepreneurs (Parent R43/R44 Clinical Trial Optional) | PAR-27-039 | NIH | 93.121 | January 5, 2027 | Not listed | Same assistance listing 93.121 as 1 award here |
| Small Business Transition Grant for New Entrepreneurs (Parent R41/R42 Clinical Trial Optional) | PAR-27-040 | NIH | 93.121 | January 5, 2027 | Not listed | Same assistance listing 93.121 as 1 award here |
| Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required) | PAR-24-214 | NIH | 93.394 | January 7, 2027 | $375,000 | Same assistance listing 93.394 as 1 award here |
Topics of its NIH awards
Updated November 4, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-04). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.